Shareholders Approve 3.9 Million Share Increase to Equity Incentive Plan
STAA sits 85% above its 52-week low of $15.585.
Summary
STAAR Surgical shareholders approved an amendment to its equity incentive plan, authorizing an additional 3.9 million shares for future issuance, representing a potential dilution of 7.83%.
Key Events · Corporate Governance and Compliance · STAA
-
Equity Plan Expansion Approved
Shareholders approved Amendment No. 2 to the Amended and Restated Omnibus Equity Incentive Plan, increasing the shares reserved for issuance by 3,900,000. This follows the proposal outlined in the DEF 14A filing on May 4, 2026.
-
Significant Potential Dilution
This authorization represents a potential dilution of 7.83% if all 3.9 million newly reserved shares were issued, based on the 49,788,295 outstanding shares as of April 20, 2026.
-
Annual Meeting Results
All seven director nominees were elected, BDO USA, P.C. was ratified as the independent auditor, and executive compensation was approved on an advisory basis.
Analysis · STAA · Industrial Applications And Services
The approval of an additional 3.9 million shares for the equity incentive plan represents a potential dilution of 7.83% for existing shareholders. While common for attracting and retaining talent, this significant increase in authorized shares could create an overhang on the stock.
At the time of this filing, STAA was trading at $28.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $15.59 to $35.87. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.